Objective: Dietary supplementation with fermentable carbohydrate protects against body weight gain. Fermentation by the resident gut microbiota produces short-chain fatty acids, which act at free fatty acid receptor 2 (FFAR2). Our aim was to test the hypothesis that FFAR2 is important in regulating the beneficial effects of fermentable carbohydrate on body weight and to understand the role of gut hormones PYY and GLP-1.
INTRODUCTION
Obesity is currently one of the most serious global threats to human health and an important modifiable risk factor for type-2 diabetes, hypertension, and certain cancers [1e3] . Susceptibility to obesity is determined by genetic background, diet, and lifestyle. Additionally, over the past decade, it has become apparent that the resident intestinal microbiota also plays an important role in determining susceptibility to obesity [4e7] . This is partly due to the production of physiologically active metabolites during the process of microbial fermentation, which serve to harvest energy from dietary substrates that would otherwise be lost in the feces [8, 9] . This is typified by the fermentation of non-digestible carbohydrates, which, when supplemented into the diet, reduce appetite and body weight gain and improve glucose homeostasis in rodents and humans [10e12] . Key metabolites involved in transducing these beneficial metabolic effects are the short-chain fatty acids (SCFAs) acetate, propionate and butyrate [8] . Indeed, recent evidence suggests that the increased production of propionate following gastric bypass surgery for obesity is related to weight loss [13] . 1 While SCFAs can be utilized for de novo synthesis of lipids and glucose [14] and serve as an energy source, they also act as signaling molecules at the recently de-orphaned G-protein coupled receptors, free fatty acid receptor 2 (FFAR2, also known as GPR43) and FFAR3 (also known as GPR41) [15, 16] . Both receptors are expressed in various peripheral tissues, including the gastrointestinal tract, pancreas, bone marrow, spleen, thymus, lung, breast, and white adipose tissue; therefore, SCFAs may have widespread effects [15,17e20] . Within the gastrointestinal tract, FFAR2 and 3 have been localized to enteroendocrine L cells [17] . These specialized gut cells secrete the anorectic hormone peptide YY (PYY) and the incretin glucagon-like peptide-1 (GLP-1) in response to luminal nutrients, such as sugars, amino acids, and long-chain fatty acids [17, 21, 22] . The highest density of L cells is found in the colon where these nutrients are unlikely to reach significant concentrations, but where SCFAs are most concentrated [23] . This suggests that gut hormone release may be an important host response to microbial fermentation and the consequent production of SCFAs. In support of this, acetate and propionate have been shown to stimulate the secretion of GLP-1 in vitro, an effect which was attenuated by FFAR2 deletion [24] . We therefore hypothesize that SCFA activation of L cell-expressed FFAR2, contributes to the effects of microbial fermentation on host metabolism. To determine if the beneficial metabolic effects of fermentable carbohydrate are mediated by FFAR2 signaling, we used mice with targeted deletion of this receptor. We demonstrate for the first time that this receptor is essential for mediating inulin's ability to reduce food intake and protect against diet-induced obesity. FFAR2 signaling was found to drive an expansion of the PYY cell population within the colon, leading to increased circulating PYY, thus potentiating anorectic signaling by the gut. Our findings suggest that the fermentable carbohydrate stimulated expansion of PYY-expressing cells within the proximal colon is a physiologically important pathway linking diet, gut microbiota, and host metabolism. 
METHODS AND MATERIALS

Study approval
Animals and diets Male Ffar2
À/À C57BL/6 mice were obtained from Deltagen (http:// wwww.deltagen.com). The Ffar2 gene was deleted by homologous recombination, which substitutes 55 bp of Ffar2 exon 1 with the bgal-neo cassette, shifting the downstream amino acid sequence out of the reading frame [25] . Mice were maintained in cages under controlled temperature (21e23 C) and light (12 h light/12 h dark) with ad libitum access to food and water. Ffar2 À/À and WT littermates at 9 weeks of age were fed a high-fat "Western" diet containing 21% anhydrous milk-fat and 34% sucrose, supplemented with 7.5% inulin (HFI) or an isocaloric control diet supplemented with 3.3% cellulose þ 4.2% corn starch (HFC) for 14 or 2 weeks. For analysis of proliferation, Bromodeoxyuridine (2.6 mM) was administered in the drinking water for the second week of the 2-week intervention. Investigators were blinded to the sample group allocation during the experiment and analysis. [27] . Physical activity was also measured, using an OPTO-M3 sensor system (Columbus Instruments, Columbus, OH, USA), whereby ambulatory counts were a record of consecutive adjacent photo beam breaks in the horizontal space (X and Y axis). Data were presented as hourly averages for energy expenditure as well as hourly summation for ambulatory activities. The calorimeter was calibrated before each use using highly pure primary gas standards (O 2 and CO 2 ).
2.6. Fecal mass and energy content Fecal matter was collected over four days. Energy content in the feces was determined in duplicate using a bomb calorimeter (PARR 1356; John Morris Scientific Pty Limited, Australia). Briefly, feces was compressed, pelleted (PARR Instrument Company; Moline, IL, USA), and weighed. Pellets were frozen and then freeze-dried (Telstar Cryodos À80 C freeze dryer, Progen Scientific, UK) for 24 h. Each pellet was re-weighed to determine moisture content, placed in the bomb calorimeter for combustion, and energy content determined against a standard (benzoic acid).
Quantitative enzymatic determination of glycerol
Quantitative enzymatic determination of glycerol was carried out using Free Glycerol Reagent (SigmaeAldrich) following alkaline hydrolysis of triglycerides to glycerol and free fatty acids. Triplicate samples were diluted 1/5 and 10 ml was used for analysis. Real-time PCRs of ZO1 and Occludin were performed with the StepOnePlusÔ real-time PCR system and software (Applied Biosystems) using Mesa Fast qPCRÔ (Eurogentec) for detection according to the manufacturer's instructions. RPL19 RNA was chosen as the housekeeping gene. All samples were run in duplicate and data were analyzed according to the 2 ÀDCT method. The identity and purity of the amplified product was checked through analysis of the melting curve carried out at the end of amplification. Primer sequences for the targeted mouse genes are presented.
2.12. Organ culture Fresh perigonadal WAT and subcutaneous WAT fat pads (w100 mg) were cultured in 1 ml of RPMI serum free medium for 24 h as previously described [29] . Cytokines secreted were measured after 24 h by specific TNF-a ELISA (DuoSet ELISA Development kit, R&D, and ELISA Ready-SET-Go, eBioscience). Data are shown as the concentration of cytokines secreted in 1 ml of culture medium per gram of fat.
Isolation of mononuclear cells and flow cytometry
The stromal vascular fraction (SVF) containing mononuclear cells and pre-adipocytes was extracted from adipose tissue as previously described [29] and cells were stained with antibodies conjugated to fluorochromes, CD45 (30-F1), CD3 (145-2C11), CD4 (GK1. acetic acid for 15 min. Colonic PYY, GLP-1, and substance P concentrations were determined using established in-house radioimmunoassays [30] . The concentration of glucose-dependent insulinotropic polypeptide (GIP) was measured using a commercially available kit (Merck Millipore). Similar to colonic peptide levels, circulating and portal vein GLP-1 and PYY concentrations were determined using inhouse radioimmunoassays. Circulating leptin was measured using a commercially available kit (Merck Millipore). in secretion buffer for 2 h at 37 C. Supernatants were collected and centrifuged. Cells were treated with lysis buffer containing: 50 mM TriseHCl, 150 mM NaCl, 1% IGEPAL-CA 630, 0.5% deoxycholic acid, and one tablet of complete EDTA-free protease inhibitor cocktail (Roche). PYY and GLP-1 were assayed in supernatants and cell extracts by radioimmunoassay as previously described [32, 33] . Hormone secretion was expressed as a fraction of the total of that hormone.
Immunofluorescence and microscopy
7 mm wax embedded sections were stained for PYY using primary polyclonal rabbit anti-PYY (1:1000, Abcam, ab22663), with secondary FITC-conjugated chicken anti-rabbit antibody (1:200, Abcam, ab6825). Staining for GLP-1 was carried out using primary polyclonal mouse anti-GLP-1 with secondary TRITC-conjugated goat anti-mouse (1:200, Abcam, ab5867). BrdU was stained for using primary monoclonal mouse anti-BrdU (1:100, Sigma, 13843420001) with secondary TRITC-conjugated polyclonal goat F(Ab) anti-mouse (1:200). 5HT was stained for using primary goat anti-5HT (1:500 Abcam, ab66047) with polyclonal donkey anti-goat (1:50, Abcam, ab6566). Nuclei were stained with DAPI (4 0 ,6-diamidino-2-phenylindole) in Fluroshield (Abcam). Immunofluorescent images were acquired on a Carl Zeiss Axiovert 100S TV microscope. The operator performing the cellcounting was blinded to the groupings.
PYY-GFP organoid culture and treatments
Mouse intestinal crypts from transgenic PYY-GFP mice (a kind gift from Prof. Rodger Liddle, Duke University) [34] were isolated, cultured, and grown into organoids as described previously [35] .
Crypts were cultured in advanced Dulbecco's modified Eagle's medium/F12 containing 100 units/mL penicillin/streptomycin, 10 mM HEPES, 2 mM Glutamax, supplements N2 (1Â) and B27 (1Â), and 50 ng/mL mouse epidermal growth factor (all from Life Technologies); and 1 mM N-acetylcysteine (SigmaeAldrich) and mouse Noggin and mouse R-spondin-1, both as 10% conditioned medium. Medium was changed every 2 days. On day 2 after splitting, either 10 mM CFMB or 10 mM AR420626 was added to the medium. For control mouse organoids, regular medium without CFMB or AR420626 was used. Organoids were imaged on day 6, after 96 h of treatment, using a Nikon Inverted Spinning Disk confocal equipped with a humidified, temperature control environmental chamber. Images were obtained using NIS Elements AR software. To count the number of PYY positive cells in each organoid we obtained a continuous z-dimension stack (step size: 5 mM). 30.67 AE 3.65%, p < 0.001) ( Figure 1A ). MRI analysis revealed that differences in body weight were due to decreased adiposity (p < 0.05) ( Figure 1B ). As expected, inulin supplementation also reduced liver triglyceride (p < 0.05) and leptin concentrations (p < 0.05) in WT mice, corresponding to lower fat mass (Figure 1CeD ). Taken together, these data demonstrate that the ability of inulin to prevent weight gain in response to HFD is FFAR2-dependent. The reduction in body weight observed in WT mice supplemented with inulin was associated with decreased food intake ( [36, 37] , while anorexigenic neuropeptide Pomc expression is reduced [38] . As such gene expression of these neuropeptides serves as an indicator of anorectic drive. While we found that inulin supplementation did not alter Pomc or Npy expression (Figure 1FeG ), Agrp expression was decreased in WT but not Ffar2
À/À mice (p < 0.05) ( Figure 1H ), suggesting that inulin acts via FFAR2 to decrease hypothalamic orexigenic drive. Body weight is not only a function of food intake, it is also governed by energy absorption and expenditure. To determine whether the reduction in body weight was associated with alterations in energy expenditure, we measured locomotor activity and basal metabolic rate, both of which were unaffected by diet or genotype ( Figure 1IeJ ). As energy expenditure is influenced by brown adipose tissue thermogenesis, gene expression of the thermogenic protein Ucp1 was measured. In agreement with recently published data, gene expression of Ucp1 was unchanged following inulin supplementation ( Figure 1K ) [39] . To assess energy absorption, fecal energy content was measured. Inulin supplementation modestly reduced fecal energy loss in WT and Ffar2 À/À mice (p < 0.05) ( Figure 1L ). Collectively, these data demonstrate the effect of inulin on body weight was not due to increased energy expenditure or fecal energy loss but was likely a result of the decrease in food intake.
Glucose homeostasis improvement following fermentable carbohydrate supplementation is dependent on FFAR2
Fermentable carbohydrate consumption has previously been shown to be associated with an improvement in glucose homeostasis [11] . Prior to dietary intervention, all groups were equally glucose tolerant and insulin sensitive (Supplementary Figure 2) . After 13 weeks, WT mice given inulin exhibited improved glucose tolerance (p < 0.05). However, insulin tolerance was unchanged (Supplementary Figure 2) . Interestingly, inulin lowered fasted glucose levels in WT and Ffar2 À/À mice via a non-FFAR2 mediated mechanism (p < 0.01) (Supplementary Figure 2) .
3.3. Deletion of FFAR2 does not alter the microbial density of Bifidobacterium spp., Lactobacillus spp., or total bacteria within the colon Colonic microbial density and species composition influence inulin fermentation and SCFA production. Therefore, it was possible that FFAR2 could drive alterations in microbial diversity and account for the metabolic benefits we observed. To address this, we carried out targeted enquiry of bacterial species that are important for inulin fermentation and that are increased by fermentable carbohydrate supplementation. Total bacterial numbers were increased by inulin supplementation (p < 0.001), consistent with previous studies [40] . Additionally, species belonging to the Bifidobacterium spp., which play a key role in fermenting inulin, were also increased (p < 0.05), while the abundance of Lactobacillus spp. was unaltered. Importantly, there were no effects of genotype on microbial number or species-specific density ( Figure 2) ; hence, the FFAR2-dependent effects of inulin on body weight are not driven by alterations in bacterial cell density. Figure 2d) (p < 0.01). However, it is unlikely that reduced CD4 þ T-cell infiltration directly influenced glucose homeostasis as immune cell populations were also decreased by Ffar2 deletion, which was not associated with such improvements. Conversely, one observation, which could account for improved glucose homeostasis, was that spontaneous TNF-a release from visceral WAT decreased following inulin supplementation in WT animals (p < 0.01) (Supplementary Figure 3j) . ) ( Figure 3A) . The ability of inulin to increase portal vein PYY appears to be reduced and not completely abolished by FFAR2 deletion, as the difference between WT HFI and Ffar2 À/À HFI groups was not significant. In contrast to PYY, GLP-1 release was increased independently of FFAR2 following inulin supplementation (WT: p < 0.05, Ffar2 À/À : 0.0548) ( Figure 3B ), demonstrating that inulin differentially regulates PYY and GLP-1 secretion via FFAR2-dependent and independent mechanisms respectively. While SCFAs are implicated in mediating the effects of inulin due to the selectivity of FFAR2 for these metabolites, we confirmed their role in a primary colonic cell model [31] . Exposure to mixed SCFAs, in the same ratio as found in the gut following inulin fermentation [46] , increased secretion of PYY by 127% (p < 0.0001) and GLP-1 by 54% (p < 0.001) compared to baseline. This effect was not observed in Figure 3E ). In contrast, inulin significantly increased colonic GLP-1 regardless of genotype and thus was not receptor dependent (WT: p < 0.01, Ffar2 À/À : p < 0.01) ( Figure 3F ). These effects were specific to L cells as hormones expressed in developmentally distinct enteroendocrine cell types such as GIP and Substance P were unchanged. Crypt length as well as goblet and enterochromaffin cell densities were also unaffected (Supplementary Figure 5) . Colonic PYY and GLP-1 concentrations reflected the circulating concentrations, indicating that inulin increases gut hormone release by increasing the amount of PYY and GLP-1 within the colon.
Fermentable carbohydrate supplementation increases PYY cell density in the proximal colon via FFAR2
To determine whether the increased colonic PYY and GLP-1 concentrations were due to an increase in L cell density, we used Figure 6) . In WT mice, inulin supplementation caused an 87% increase in PYY (p < 0.05) and 73% increase in GLP-1 cell density (p < 0.05). Whereas, in Ffar2 À/À mice, GLP-1 cell density was increased by 60% (p < 0.05), and PYY cell-density was unchanged (p ¼ 0.23) (Figure 4 ). While the expansion of the PYY-expressing cell population is dependent on FFAR2, the expansion of the GLP-1-expressing cell population occurs independently of FFAR2. We also observed an increase in the density of cells that co-express both hormones ( Figure 4C) . Therefore, the increase in GLP-1 cell density appears to be due to GLP-1 being expressed in cells that would otherwise have been PYY singly labeled cells. Conversely, the increase in PYY cell density was due to an expansion of L cells that did not express GLP-1. These data demonstrate that inulin increases colonic gut hormone concentrations by increasing the density of specific enteroendocrine cell types in the colon.
To assess whether increased PYY cell density was due to an increase in the rate of PYY cell formation, bromodeoxyuridine (BrdU) was administered to mice for the second week of a 2-week intervention. BrdU incorporates into the DNA of dividing cells, allowing identification of newly formed cells. PYY-expressing cells, which stained positive for BrdU, were 129% more abundant in WT (p ¼ 0.0003) but not Ffar2 elucidate the mechanism by which inulin regulates the expansion of PYY cells, we measured gene expression of these transcription factors. While Pax6, Foxa1 and Foxa2 were unaltered following inulin feeding, Pax4 was significantly and receptor-dependently increased (WT: p ¼ 0.017, Ffar2 À/À : p ¼ 0.69) ( Figure 5 ). This suggests that Pax4 may link FFAR2 activation to the expansion of the PYY cell population.
FFAR2 but not FFAR3 activation increases PYY cell density in vitro
To determine the relative roles of FFAR2 and FFAR3 on PYY and GLP-1 cell density, we used selective agonists for FFAR2 (CFMB) [52] and FFAR3 (AR420626) [35] in an in vitro organoid culture. The doses of each agonist were chosen based on previous reports in the literature and because they did not result in cellular toxicity in our organoid model.
Tolhurst et al. demonstrate that a dose of 30 mM of CFMB increases calcium flux in isolated colonic cultures [45] . Whilst Nohr et al. [46] used doses of 10 mM and 30 mM of both agonists based on their potencies. CFMB is reported to have an IC 50 of 4.7 mM at FFAR2 but displays no activity at FFAR3 up to 1 mM, while AR420626 is reported to have an IC 50 value of 117 nM for FFAR3 and does not activate FFAR2 at concentrations up to 100 mM in cAMP accumulation assays [52] .
Primary intestinal crypts from PYY-GFP mice were cultured in a threedimensional, growth-factor rich environment, recapitulating in vivo colonic multi-lineage differentiation [35, 53] . Exposure of colonic organoids to FFAR2 agonist CFMB led to increased PYY, but not GLP-1 cell density (p < 0.001) ( Figure 6 ). In contrast, the FFAR3 agonist had no effect on PYY or GLP-1 cell density. It therefore appears that SCFAs act via FFAR2 but not FFAR3 to increase PYY cell density.
DISCUSSION
The discovery that gut microbiota influences physiology and, in certain circumstances, may cause disease pathologies has led to an intensive research effort to unravel microbiotaehost interactions. Understanding the effects of microbial fermentation on host metabolism has been of particular interest, because consumption of fermentable carbohydrate reduces appetite and prevents body weight gain [10e12,20] . Evidence points to the production of SCFAs by the gut microbiota as an important appetite regulatory signal. In this study, we report for the first time that FFAR2 expression is essential for inulin to exert these beneficial effects. As such, targeting this pathway in man could be a viable means of preventing obesity. Our key finding is that fermentable carbohydrate drives an increase in PYY-cell density within the colon, which is mediated via FFAR2 and results in increased circulating PYY concentrations. This is associated with a reduction in food intake and protection against diet-induced obesity. Furthermore, FFAR2 but not FFAR3 activation at the level of the intestinal epithelium is sufficient to increase PYY cell density in isolated organoids. We also demonstrate that inulin, acting via FFAR2, stimulates the expression of Pax4, a transcription factor that has previously been shown to be essential for differentiation of PYY cells in the fetal mouse colon [54] . We therefore propose that inulin, following microbial fermentation to SCFAs, acts via FFAR2 to influence cellular differentiation pathways and promote PYY cell fate. Increasing the density of PYY cells provides the colon with a greater potential for release of PYY, which is known to reduce food intake. A number of interesting questions remain to be answered. As FFAR2 activation drives changes in enteroendocrine cell fate, is it expressed by progenitor cells, either by epithelial LgR5þ stem cells or by endocrine NGN3þ progenitors, or does FFAR2 act later in the enteroendocrine development pathway? Lineage tracing experiments could allow the determination of the origin of newly generated PYY singly labeled cells. Furthermore, it will be important in the future to determine the intracellular pathways triggered by FFAR2 activation that lead to altered endocrine cell fate. Understanding these processes could identify targets for manipulation of endocrine cell fate in order to treat disease. While we describe an important role for FFAR2 in driving increased PYY secretion, FFAR2 signaling has previously been reported to influence food intake and body weight via the inhibition of ghrelin secretion [52] and the suppression of insulin signaling in adipocytes [55] . As such, it is likely that SCFAs exert their effects on metabolism via multiple complementary pathways. However, fermentation occurs primarily in the colon where there is a high density of L cells, suggesting that the mechanism described here plays a critical role in transducing the effects of SCFAs on appetite. The luminal concentrations of SCFAs within the colon have been estimated to be 70e130 mmol [56] . This exceeds the concentration range to which FFAR2 is sensitive and would suggest that colonic FFAR2 is constantly active. However, due to a number of factors, it is unlikely that FFA receptors are exposed to these concentrations. Firstly, in the colon, the microbiota are compartmentalized to the outer mucus layer; the inner mucus layer contains almost no microbiota and serves to protect the epithelium. Therefore, there is a separation between the bacteria and the epithelium, through which a concentration gradient would form. In the distal colon, the w50 mm inner mucus layer has been shown to be replaced every hour [57] . Secondly, the crypt opening is narrow, creating further impediment to the diffusion of SCFAs. Finally, SCFAs are rapidly absorbed by the epithelial cells, thereby depleting the concentration of SCFAs in the immediate environment. The precise concentration of the different SCFAs at the level of the colonic epithelium is not known. However, based on the EC 50 values of SCFAs for FFAR2 one might imagine that the local SCFA concentration would be in the micromolar range [15] .
Additionally, there are likely to be non-receptor mediated actions of SCFAs following dietary fermentable carbohydrate supplementation.
Recently, it has been demonstrated that acetate alters hypothalamic neuronal activity [58] . However, the central actions of SCFAs on food intake, to date, have only been observed acutely following intracerebroventricular administration [58] . In contrast, our data describe long-term FFAR2-dependent adaptations, which may underlie the ability of fermentable carbohydrates to exert sustained reductions in body weight. SCFA also have been reported to act via a non-receptor mediated mechanism within the liver and adipose tissue to reduce peroxisome proliferator-activated receptor gamma (PPAR-g) expression, thereby preventing body weight gain and improving insulin sensitivity [59] . These observations are described following dietary supplementation with SCFAs as opposed to fermentable carbohydrate. In contrast to the microbiota-dependant production of SCFAs from fermentable carbohydrate, dietary SCFAs can be absorbed earlier in the gastrointestinal tract, and therefore colonic mechanisms would be largely evaded. Collectively, the accumulating data within this field reveal a complex system of intertwined receptor-and non-receptor mediated mechanisms that act together to prevent body weight gain.
In agreement with previous studies, we also find that fermentable carbohydrate increased GLP-1 secretion [44, 45] . This could explain the decreased fasted plasma glucose observed with inulin supplementation due to the insulinotropic effects of GLP-1 [60] . In support of this, it has recently been demonstrated that dibenzapine administration, which blocks the Notch signaling pathway, increases intestinal GLP-1 cell numbers in a HFD model of impaired glucose tolerance and improves insulin responses to glucose and glucose tolerance [61] . Alternatively, recently published data suggest that the improvements in glucose homeostasis could be associated with FFAR3-dependant alterations in intestinal gluconeogenesis [62, 63] . Propionate signals via FFAR3 expressed on periportal afferent neurons and via a gut-brain neural circuit to induce intestinal gluconeogenesis, which results in improved glucose homeostasis [63] . Similar to the increase in PYY, the increase in circulating GLP-1 was associated with a greater cell density. Previously Cani et al. have demonstrated that fermentable carbohydrate increases colonic GLP-1 cell density in association with increased expression of the transcription factor Neurogenin3 (NGN3) [44, 64] . NGN3 acts upstream of Pax4, Pax6, Foxa1, and Foxa2 and is responsible for determining an enteroendocrine cell fate. This suggests that fermentable carbohydrate increases production of new enteroendocrine cells. However, the observed increase in GLP-1 cell density was not associated with alterations in Pax4, Pax6, Foxa1, and Foxa2 expression, indicating that these transcription factors are not responsible for driving increases in GLP-1 cell density in response to inulin. Contrary to the increase in PYY cell density, the increase in GLP-1 cell density occurred independently of FFAR2. In agreement with a number of other studies, we found only partial co-localization of PYY and GLP-1 [23,65e69] , despite the prevailing view that GLP-1 and PYY are coexpressed in L cells and co-stored in secretory vesicles. This may be because the degree of co-localization varies depending on location along the proximaledistal axis, between species, with metabolic state, and between studies [66, 67] . It is therefore of great interest to identify factors that differentially modulate the expression of these two gut hormones.
The mechanism underlying the increase in GLP-1 cell density does not appear to be FFAR3 activation, as FFAR3 agonism did not alter the density of GLP-1 cells in organoids. Furthermore, Ffar2 deletion has previously been shown to prevent SCFA-induced GLP-1 release in vitro to a greater degree than FFAR3 deletion [24] , suggesting that FFAR3 may be less important in mediating SCFA signaling in L cells. One possibility is that SCFAs cross the cell membrane via non-ionic diffusion and may act intracellularly to increase GLP-1 cell density [70] . However, such a mechanism perhaps would be associated with a more generalized proliferative effect compared to the very specific effects that we observed. Finally, and more plausibly, additional bioactive fermentation products may stimulate an expansion of the GLP-1 cell population. Undoubtedly, elucidation of this mechanism will be an important discovery that could improve treatment options for diabetes.
CONCLUSION
We have demonstrated that FFAR2 is pivotal for transducing the beneficial metabolic effects of fermentable carbohydrate. By stimulating microbial SCFA production using inulin, we demonstrate that these fermentation products act via FFAR2 to drive an expansion of the PYY cell population within the proximal colon. The resulting increase in cell density leads to increased circulating PYY, which previously has been shown to reduce appetite [71] . This presents a new understanding of gut physiology whereby the gut exhibits cellular plasticity, allowing it to respond to alterations in dietary composition. Such changes alter the capacity for anorectic signaling ( Figure 7 ). This paradigm likely represents a more general physiological mechanism and, if true, begs the question as to whether other nutrients or microbial metabolites influence enteroendocrine plasticity in order to alter host physiology. By targeting this pathway with drugs or nutraceuticals, it may be possible to prime the colon to produce a greater anorectic signal in response to nutrients to treat or prevent obesity. Figure 7 : Mechanism by which fermentable carbohydrate prevents body weight gain. Following consumption, fermentable carbohydrate (FCH) is fermented by gut microbiota to produce short chain fatty acids (SCFAs). SCFAs subsequently act at free fatty acid receptor 2 (FFAR2) within the colon to enhance PYY cell density, thereby augmenting the capacity of the gut to release PYY. PYY acts to reduce orexigenic drive via AgRP neurons within the arcuate nucleus and reduce food intake.
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